Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination-Reference-Cited by-同舟云学术

Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination

Published:2006-08 Issue:8 Volume:74 Page:4954-4959
ISSN:0019-9567
Container-title:Infection and Immunity
language:en
Short-container-title:Infect Immun

Author:

Ha Sang-Jun¹,Park Su-Hyung¹,Kim Hye-Ju¹,Kim Seung-Chul²,Kang Hyang-Ju¹,Lee Eun-Gae²,Kwon Soon-Geon²,Kim Byong-Moon³,Lee Sung-Hee³,Kim Won-Bae³,Sung Young-Chul¹,Cho Sang-Nae²⁴

Affiliation:

1. Division of Molecular and Life Sciences, Postech Biotech Center, Pohang University of Science & Technology, San 31 Hyoja-dong, Pohang 790-784, Korea

2. Department of Microbiology and Brain Korea 21 Project for Medical Sciences, Yonsei University College of Medicine, 134 Shinchon-dong, Seoul 120-752, Korea

3. Research Laboratories, Dong-A Pham. Co., Ltd., Yongin-si, Kyunggi-do 449-900, Korea

4. The International Vaccine Institute, Seoul 151-600, Korea

Abstract

ABSTRACT Tuberculosis subunit vaccines codelivered with interleukin-12 (IL-12)-encapsulated microspheres (IL-12EM) are designed for a sustained release of IL-12 and could induce strong Th1 immune responses specific to Ag85A and ESAT-6. The adjuvant combination of IL-12EM plus AS01B was a more efficient way to induce a sustained Th1 immunity and protection against Mycobacterium tuberculosis.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Immunology,Microbiology,Parasitology

Link

https://journals.asm.org/doi/pdf/10.1128/IAI.01781-05

Reference30 articles.

1. Anacker, R. L., W. R. Barclay, W. Brehmer, C. L. Larson, and E. Ribi. 1967. Duration of immunity to tuberculosis in mice vaccinated intravenously with oil-treated cell walls of Mycobacterium bovis strain BCG. J. Immunol.98:1265-1273.

2. Bojang, K. A., P. J. Milligan, M. Pinder, L. Vigneron, A. Alloueche, K. E. Kester, W. R. Ballou, D. J. Conway, W. H. Reece, P. Gothard, L. Yamuah, M. Delchambre, G. Voss, B. M. Greenwood, A. Hill, K. P. McAdam, N. Tornieporth, J. D. Cohen, and T. Doherty. 2001. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet358:1927-1934.

3. Brandt, L., T. Oettinger, A. Holm, A. B. Andersen, and P. Andersen. 1996. Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J. Immunol.157:3527-3533.

4. Colditz, G. A., T. F. Brewer, C. S. Berkey, M. E. Wilson, E. Burdick, H. V. Fineberg, and F. Mosteller. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA271:698-702.

5. Crotts, G., and T. G. Park. 1998. Protein delivery from poly(lactic-co-glycolic acid) biodegradable microspheres: release kinetics and stability issues. J. Microencapsul.15:699-713.

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine delivery systems for immunization;Novel Formulations and Future Trends;2024

2. Advances in engineering and delivery strategies for cytokine immunotherapy;Expert Opinion on Drug Delivery;2023-05-03

3. Development of (Inhalable) Dry Powder Formulations of AS01B-Containing Vaccines Using Thin-Film Freeze-Drying;International Journal of Pharmaceutics;2022-06

4. Synthesis, Characterization, and In Vivo Cytokinome Profile of IL-12-Loaded PLGA Nanospheres;Journal of Immunology Research;2022-04-14

5. Development of Dry Powder Formulations of AS01_Bcontaining vaccines using Thin-Film Freeze-Drying;2022-03-01